LU92976I2 - Asfotase alfa - Google Patents

Asfotase alfa Download PDF

Info

Publication number
LU92976I2
LU92976I2 LU92976C LU92976C LU92976I2 LU 92976 I2 LU92976 I2 LU 92976I2 LU 92976 C LU92976 C LU 92976C LU 92976 C LU92976 C LU 92976C LU 92976 I2 LU92976 I2 LU 92976I2
Authority
LU
Luxembourg
Prior art keywords
amino acid
absent
acid sequence
asfotase alfa
salp
Prior art date
Application number
LU92976C
Other languages
English (en)
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of LU92976I2 publication Critical patent/LU92976I2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001Alkaline phosphatase (3.1.3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
LU92976C 2007-05-11 2016-02-10 Asfotase alfa LU92976I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
PCT/CA2008/000923 WO2008138131A1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Publications (1)

Publication Number Publication Date
LU92976I2 true LU92976I2 (en) 2016-04-11

Family

ID=40001639

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92976C LU92976I2 (en) 2007-05-11 2016-02-10 Asfotase alfa

Country Status (25)

Country Link
US (1) US20100297119A1 (nl)
EP (3) EP2662448B1 (nl)
JP (1) JP5732603B2 (nl)
AT (1) ATE536413T1 (nl)
AU (1) AU2008250945B2 (nl)
BR (2) BR122019000505B1 (nl)
CA (1) CA2687001C (nl)
CY (1) CY2016005I1 (nl)
DE (1) DE202008018131U1 (nl)
DK (3) DK2158319T3 (nl)
ES (3) ES2380546T3 (nl)
HK (3) HK1141047A1 (nl)
HR (1) HRP20140416T1 (nl)
HU (2) HUE031655T2 (nl)
IL (1) IL202057A0 (nl)
LT (1) LTC2368999I2 (nl)
LU (1) LU92976I2 (nl)
ME (1) ME01828B (nl)
NL (1) NL300798I1 (nl)
NO (1) NO2016002I2 (nl)
PL (3) PL2662448T3 (nl)
PT (3) PT2158319E (nl)
RS (1) RS53302B (nl)
SI (2) SI2662448T1 (nl)
WO (1) WO2008138131A1 (nl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4874954B2 (ja) * 2004-04-21 2012-02-15 エノビア ファーマ インコーポレイティド 骨送達複合体ならびにタンパク質に骨を標的化させるためのその使用方法
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
KR101580937B1 (ko) 2007-06-01 2015-12-31 유니버시티 오브 매릴랜드, 발티모어 면역글로불린 불변영역 Fc 수용체 결합제
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
BR112012027765A2 (pt) * 2010-04-30 2019-09-24 Enobia Pharma Inc métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
DK2598533T3 (en) 2010-07-28 2019-04-23 Gliknik Inc Fusion proteins of natural human protein fragments to create in an orderly fashion multimerized immunoglobulin FC compositions
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
CA2852874A1 (en) * 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
SG11201606060WA (en) * 2014-01-24 2016-08-30 Am Pharma Bv Chimeric alkaline phosphatase-like proteins
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
US10449236B2 (en) * 2014-12-05 2019-10-22 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
MX2018002121A (es) * 2015-08-17 2018-06-18 Alexion Pharma Inc Elaboracion de fosfatasas alcalinas.
WO2017058822A1 (en) * 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) * 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ, インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3436052A4 (en) * 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. TREATMENT OF MUSCLE WEAKNESS USING ALKALINE PHOSPHATASES
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES
WO2017214321A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
WO2018004517A1 (en) 2016-06-27 2018-01-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
IL266977B2 (en) * 2016-11-30 2024-01-01 Purdue Research Foundation Fracture-targeted bone regeneration using thyroid hormone receptor stimulation
CA3043261A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Manufacturing optimization of gl-2045, a multimerizing stradomer
EP3592372A4 (en) * 2017-03-09 2021-01-13 Alexion Pharmaceuticals, Inc. GLYCOPROTEIN MANUFACTURING PROCESS
JP2020512363A (ja) * 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ, インコーポレイテッド 成人及び青年における低ホスファターゼ症(hpp)を治療する方法
CA3087569A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
CA3094173A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
EP4275761A3 (en) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
MX2022007114A (es) * 2019-12-09 2022-07-11 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos.
KR20230117327A (ko) * 2020-09-03 2023-08-08 어빈 에스.와이. 첸 가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
MX2023009463A (es) * 2021-02-12 2023-09-21 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos para su uso.
WO2024050464A2 (en) * 2022-08-31 2024-03-07 University Of Utah Research Foundation Gja1-20k compositions and methods for mitigating ischemia-reperfusion injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
ATE314482T1 (de) 1993-10-25 2006-01-15 Canji Inc Rekombinante adenoviren-vektor und verfahren zur verwendung
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
AU1920201A (en) 1999-11-16 2001-05-30 Genzyme Corporation Improved regulatory elements for delivery to the liver
ATE437221T1 (de) 2001-05-14 2009-08-15 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
JP4874954B2 (ja) 2004-04-21 2012-02-15 エノビア ファーマ インコーポレイティド 骨送達複合体ならびにタンパク質に骨を標的化させるためのその使用方法
US20070081984A1 (en) * 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
JP2008504270A (ja) 2004-06-23 2008-02-14 ジェンザイム・コーポレイション 嚢胞性疾患を処置するための方法および組成物
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
MX2007006524A (es) 2004-12-01 2007-06-22 Genzyme Corp Metodos para el suministro dirigido de material genetico al higado.

Also Published As

Publication number Publication date
EP2158319A4 (en) 2010-07-21
JP2010526543A (ja) 2010-08-05
SI2662448T1 (sl) 2017-05-31
NO2016002I2 (no) 2016-02-02
PL2368999T3 (pl) 2014-08-29
HRP20140416T1 (hr) 2014-06-20
IL202057A0 (en) 2011-08-01
BRPI0811198B1 (pt) 2021-03-09
BR122019000505A2 (pt) 2021-12-14
JP5732603B2 (ja) 2015-06-10
HUE031655T2 (hu) 2017-07-28
EP2158319B1 (en) 2011-12-07
PL2158319T4 (pl) 2016-04-29
AU2008250945A1 (en) 2008-11-20
ES2380546T3 (es) 2012-05-16
EP2662448B1 (en) 2016-12-21
CY2016005I2 (el) 2016-08-31
HUS1600005I1 (hu) 2016-02-29
US20100297119A1 (en) 2010-11-25
HK1162589A1 (en) 2012-08-31
BRPI0811198A2 (pt) 2014-10-21
CY2016005I1 (el) 2016-08-31
BRPI0811198A8 (pt) 2018-07-31
ES2619332T3 (es) 2017-06-26
WO2008138131A4 (en) 2008-12-31
NL300798I2 (nl) 2016-03-16
PT2158319E (pt) 2012-03-06
ATE536413T1 (de) 2011-12-15
NL300798I1 (nl) 2016-03-16
EP2368999A1 (en) 2011-09-28
DK2662448T3 (en) 2017-03-20
PT2368999E (pt) 2014-05-26
DK2158319T3 (da) 2012-03-19
BRPI0811198B8 (pt) 2021-05-25
LTC2368999I2 (lt) 2017-09-25
ES2471915T3 (es) 2014-06-27
ME01828B (me) 2014-12-20
EP2158319A1 (en) 2010-03-03
WO2008138131A1 (en) 2008-11-20
PT2662448T (pt) 2017-03-29
WO2008138131A9 (en) 2009-08-06
HK1141047A1 (en) 2010-10-29
AU2008250945B2 (en) 2013-12-12
NO2016002I1 (nl) 2016-02-02
DE202008018131U1 (de) 2011-12-30
CA2687001C (en) 2019-02-12
RS53302B (en) 2014-08-29
CA2687001A1 (en) 2008-11-20
DK2368999T3 (da) 2014-05-26
AU2008250945A2 (en) 2009-12-24
HK1191372A1 (zh) 2014-07-25
EP2662448A1 (en) 2013-11-13
PL2662448T3 (pl) 2017-07-31
PL2158319T3 (pl) 2012-05-31
BR122019000505B1 (pt) 2022-01-18
SI2368999T1 (sl) 2014-07-31
LTPA2016004I1 (lt) 2016-02-25
EP2368999B1 (en) 2014-03-12

Similar Documents

Publication Publication Date Title
LU92976I2 (en) Asfotase alfa
RS52843B (en) THE NEW IS THE HYDROGEN SULPHATE
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
DK1817164T3 (da) Åndbare vind- og vandtætte syede genstande
ATE481987T1 (de) Verfahren zur radiofluoridierung von biologisch aktiven vektoren
MX347545B (es) Polipeptidos con actividad xilanasa.
MY151985A (en) Dental wipe
BRPI0414598A (pt) indóis substituìdos
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
TW200630367A (en) Substituted adenines and the uses thereof
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
BR0110999A (pt) Misturas de adesivos aquosos
DK2084198T3 (da) Beklædningssammensætning
DE602007010969D1 (de) Zytokinderivate
MY150639A (en) T cell adhesion molecule and antibody thereto
FR2902101B1 (fr) Peptides a activite anti-proliferative
CY1115263T1 (el) Αλκαλικη φωσφαταση στοχευμενη στα οστα, κιτ και μεθοδοι χρησης αυτων